NF1 and neurofibromatosis-Noonan syndrome: Our secondary objectives were twofold: (i) to evaluate inter-rater agreement among clinicians experienced in diagnosing NF-NS and assess the effectiveness of phenotypic evaluation; and (ii) to determine whether there is an increased risk of CHM in NF-NS patients, regardless of the type of NF1 PV, compared to those with ‘classic’ NF1.